Equities analysts predict that Solid Biosciences Inc (NASDAQ:SLDB) will post earnings per share of ($0.59) for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Solid Biosciences’ earnings, with the highest EPS estimate coming in at ($0.58) and the lowest estimate coming in at ($0.59). Solid Biosciences reported earnings of ($0.52) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 13.5%. The firm is scheduled to issue its next earnings results on Friday, August 9th.

On average, analysts expect that Solid Biosciences will report full year earnings of ($2.53) per share for the current financial year, with EPS estimates ranging from ($2.93) to ($2.27). For the next fiscal year, analysts forecast that the company will post earnings of ($2.10) per share, with EPS estimates ranging from ($2.14) to ($2.05). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that follow Solid Biosciences.

Solid Biosciences (NASDAQ:SLDB) last released its quarterly earnings data on Monday, May 13th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.63) by ($0.22).

A number of research analysts recently issued reports on SLDB shares. Chardan Capital restated a “buy” rating and set a $15.00 price objective on shares of Solid Biosciences in a research report on Thursday, February 7th. Svb Leerink lowered Solid Biosciences from an “outperform” rating to a “market perform” rating in a research report on Friday, February 8th. Citigroup upgraded Solid Biosciences from a “sell” rating to a “neutral” rating and set a $8.00 price objective for the company in a research report on Friday, February 8th. Leerink Swann lowered Solid Biosciences from an “outperform” rating to a “market perform” rating in a research report on Thursday, February 7th. Finally, ValuEngine upgraded Solid Biosciences from a “hold” rating to a “buy” rating in a research report on Tuesday, March 19th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and one has assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $20.11.

NASDAQ:SLDB traded down $0.41 during midday trading on Wednesday, reaching $5.91. 973,108 shares of the company traded hands, compared to its average volume of 876,660. Solid Biosciences has a twelve month low of $5.23 and a twelve month high of $54.84. The firm has a market capitalization of $209.30 million, a P/E ratio of -2.63 and a beta of 1.68. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.31 and a quick ratio of 10.31.

In other news, Director Juan Andrey Zarur sold 8,000 shares of the company’s stock in a transaction on Wednesday, May 8th. The stock was sold at an average price of $10.00, for a total value of $80,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Boxer Capital, Llc sold 450,000 shares of the company’s stock in a transaction on Thursday, March 28th. The shares were sold at an average price of $9.88, for a total value of $4,446,000.00. The disclosure for this sale can be found here. Insiders own 31.20% of the company’s stock.

Several institutional investors have recently made changes to their positions in SLDB. Jennison Associates LLC purchased a new position in Solid Biosciences in the fourth quarter valued at about $21,109,000. Partner Fund Management L.P. boosted its stake in shares of Solid Biosciences by 66.9% during the 4th quarter. Partner Fund Management L.P. now owns 1,335,080 shares of the company’s stock worth $35,780,000 after acquiring an additional 535,303 shares in the last quarter. BlackRock Inc. boosted its stake in shares of Solid Biosciences by 56.0% during the 4th quarter. BlackRock Inc. now owns 1,214,410 shares of the company’s stock worth $32,546,000 after acquiring an additional 436,161 shares in the last quarter. Vanguard Group Inc boosted its stake in shares of Solid Biosciences by 82.0% during the 3rd quarter. Vanguard Group Inc now owns 675,180 shares of the company’s stock worth $31,855,000 after acquiring an additional 304,286 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in shares of Solid Biosciences by 82.0% during the 3rd quarter. Vanguard Group Inc. now owns 675,180 shares of the company’s stock worth $31,855,000 after acquiring an additional 304,286 shares in the last quarter. Institutional investors and hedge funds own 63.39% of the company’s stock.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, engages in identifying and developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, an adeno-associated viral vector-mediated gene transfer, which is in a Phase I/II clinical trial to restore functional dystrophin protein expression in patients' muscles.

Further Reading: Do stock splits help investors?

Get a free copy of the Zacks research report on Solid Biosciences (SLDB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.